Cargando…
EGFR-TKI在非小细胞肺癌中耐药机制的研究进展
Nowadays, lung cancer is the malignant tumor of the highest morbidity and mortality over the world, and non-small cell lung cancer (NSCLC) makes up about 80%. There is a great many NSCLC patients have been in advanced stage when diagnosed. As a result, people pay more attention to curing advanced NS...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6015174/ https://www.ncbi.nlm.nih.gov/pubmed/24113007 http://dx.doi.org/10.3779/j.issn.1009-3419.2013.10.07 |